Effects of green tea compound epigallocatechin-3-gallate against Stenotrophomonas maltophilia infection and biofilm

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Vidigal, Pedrina G ^a   Müsken, Mathias ^b,c   Becker, Katrin A ^d   Häussler, Susanne ^b,c   Wingender, Jost ^d   Steinmann, Eike ^b   Kehrmann, Jan ^b   Gulbins, Erich ^d   Buer, Jan ^a   Rath, Peter Michael ^a   Steinmann, Jörg ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b INSTITUTE OF INFECTION IMMUNOLOGY   (Germany)

^c HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIN; EPIGALLOCATECHIN GALLATE; CATECHIN; TEA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL SURVIVAL; BACTERIUM ISOLATE; BIOFILM; C57BL 6 MOUSE; COMPARATIVE STUDY; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MOUSE; FEMALE; GROWTH INHIBITION; IN VITRO STUDY; IN VIVO STUDY; LUNG INFECTION; MALE; MOUSE; NONHUMAN; STENOTROPHOMONAS MALTOPHILIA; TEA; ANALOGS AND DERIVATIVES; ANIMAL; BACTERIAL LOAD; C57BL MOUSE; CHEMISTRY; DRUG EFFECTS; DRUG INSTILLATION; GROWTH, DEVELOPMENT AND AGING; ISOLATION AND PURIFICATION; KINETICS; MICROBIAL SENSITIVITY TEST; MUTANT MOUSE STRAIN; PHYSIOLOGY;

ANIMALS; BACTERIAL LOAD; BIOFILMS; CATECHIN; COLISTIN; FEMALE; INSTILLATION, DRUG; KINETICS; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MICROBIAL SENSITIVITY TESTS; STENOTROPHOMONAS MALTOPHILIA; TEA;

EID: 84898893834     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0092876     Document Type: Article

References (45)

1. de Vrankrijker AM, Wolfs TF, van der Ent CK (2010) Challenging and emerging pathogens in cystic fibrosis. Paediatr Respir Rev 11:246-254.
2. Hauser AR, Jain M, Bar-Meir M, McColley SA (2011) Clinical significance of microbial infection and adaptation in cystic fibrosis. Clin Microbiol Rev 24:29-70.
3. Chernish RN, Aaron SD (2003) Approach to resistant gram-negative bacterial pulmonary infections in patients with cystic fibrosis. Curr Opin Pulm Med 9:509-515. (Pubitemid 37268216)
4. Lechtzin N, John M, Irizarry R, Merlo C, Diette GB, et al. (2006) Outcomes of adults with cystic fibrosis infected with antibiotic-resistant Pseudomonas aeruginosa. Respiration 73: 27-33.
5. Gales AC, Jones RN, Forward KR, Liñares J, Sader HS, et al. (2001) Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999). Clin Infect Dis 32(Suppl 2);S104-113. (Pubitemid 32424265)
6. Mah TF, Pitts B, Pellock B, Walker GC, Stewart PS, et al. (2003) A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance. Nature 426:306-310. (Pubitemid 37463151)
7. Arciola CR, Campoccia D, Speziale P, Montanaro L, Costerton JW (2012) Biofilm formation in Staphylococcus implant infections. A review of molecular mechanisms and implications for biofilm-resistant materials. Biomaterials 33:5967-5982.
8. Høiby N (2002) Understanding bacterial biofilms in patients with cystic fibrosis: current and innovative approaches to potential therapies. J Cyst Fibros 1:249-254.
9. Pompilio A, Pomponio S, Crocetta V, Gherardi G, Verginelli F, et al. (2011) Phenotypic and genotypic characterization of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis: genome diversity, biofilm formation, and virulence. BMC Microbiol 11:159.
10. McCaughey G, McKevitt M, Elborn JS, Tunney MM (2012) Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions. J Cyst Fibros 11:163-172.
11. Waters V, Yau Y, Prasad S, Lu A, Atenafu E, et al. (2011) Stenotrophomonas maltophilia in cystic fibrosis: serologic response on effect on lung disease. Am J Respir Crit Care Med 183:635-640.
12. Waters V, Atenafu EG, Lu A, Yau Y, Tullis E, et al. (2013) Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients. J Cyst Fibros 12:482-486.
13. Brooke JS (2012) Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin Microbiol Rev 25:2-41.
14. Pompilio A, Crocetta V, Confalone P, Nicoletti M, Petrucca A, et al. (2010) Adhesion to and biofilm formation on IB3-1 bronchial cells by Stenotrophomonas maltophilia isolates from cystic fibrosis patients. BMC Microbiol 10:102.
15. Hirasawa M, Takada K (2004) Multiple effects of green tea catechin on the antifungal activity of antimycotics against Candida albicans. J Antimicrob Chemother 53:225-229. (Pubitemid 38239954)
16. Osterburg A, Gardner J, Hyon SH, Neely A, Babcock G (2009) Highly antibiotic-resistant Acinetobacter baumannii clinical isolates are killed by the green tea polyphenol(-)-epigallocatechin-3-gallate (EGCG). Clin Microbiol Infect 15:341-346.
17. Gordon NC, Wareham DW (2010) Antimicrobial activity of the green tea polyphenol(-)-epigallocatechin-3-gallate (EGCG) against clinical isolates of Stenotrophomonas maltophilia. Int J Antimicrob Agents 36:129-131.
18. Xu X, Zhou XD, Wu CD (2011) The tea catechin epigallocatechin gallate suppresses cariogenic virulence factors of Streptococcus mutans. Antimicrob Agents Chemother 55:1229-1236.
19. Steinmann J, Buer J, Pietschmann T, Steinmann E (2013) Anti-infective properties of epigallocatechin-3-gallate (EGCG), a component of green tea. Br J Pharmacol 168:1059-1073.
20. Yoda Y, Hu ZQ, Zhao WH, Shimamura T (2004) Different susceptibilities of Staphylococcus and Gram-negative rods to epigallocatechin gallate. J Infect Chemother 10:55-58. (Pubitemid 38298046)
21. Cui Y, Oh YJ, Lim J, Youn M, Lee I, et al. (2012) AFM study of the differential inhibitory effects of the green tea polyphenol(-)-epigallocatechin- 3-gallate (EGCG) against Gram-positive and Gram-negative bacteria. Food Microbiol 29:80-87.
22. UK Cystic Fibrosis Trust Antibiotic Working Group (2009) Section 7.3: Respiratory infection with Stenotrophomonas maltophilia. In: Antibiotic treatment for cystic fibrosis, ed. UK: Cystic Fibrosis Trust, Bromley, Kent, UK.
23. Clinical and Laboratory Standards Institute (2009) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically - Twenty second information supplement: Approved standard M07-A8. CLSI, Wayne, PA, USA.
24. Rayamajhi M, Redente EF, Condon TV, Gonzalez-Juarrero, Riches DW, et al. (2011) Non-surgical intratracheal instillation of mice with analysis of lungs and lung draining lymph nodes by flow cytometry. J Vis Exp 51:2702.
25. Lloyd MH, Wolfensohn SE (1999) Practical use of distress scoring systems in the application of humane endpoints, p. 48-53. In C.F.M. . Hendriksen and D.B. . Morton 8ed.), Humane Endpoints in Animal Experiments for Biomedical Research. Royal Society of Medicine Press, London,UK.
26. Stepanović S, Vuković D, Hola V, Di Bonaventura G, Djukić S, et al. (2007) Quantification of biofilm in microtiter plates: overview of testing conditions and practical recommendations for assessment of biofilm production by staphylococci. APMIS 115:891-899. (Pubitemid 47260470)
27. Pompilio A, Scocchi M, Pomponio S, Guida F, Di Primio A, et al. (2011) Antibacterial and anti-biofilm effects of cathelicidin peptides against pathogens isolated from cystic fibrosis patients. Peptides 32:1807-1814.
28. Müsken M, Di Fiore S, Römling U, Häussler S (2010) A 96-well-plate-based optical method for the quantitative and qualitative evaluation of Pseudomonas aeruginosa biofilm formation and its application to susceptibility testing. Nat Protoc 5:1460-1469.
29. Herrmann G, Yang L, Wu H, Song Z, Wang H, et al. (2010) Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa. J Infect Dis 202:1585-1592.
30. Costerton JW, Stewart PS, Greenberg EP (1999) Bacterial biofilms: a common cause of persistent infections. Science 284:1318-1322. (Pubitemid 29289651)
31. Di Bonaventura G, Stepanović S, Picciani C, Pompilio A, Piccolomini R (2007) Effect of environmental factors on biofilm formation by clinical Stenotrophomonas maltophilia isolates. Folia Microbiol 52:86-90. (Pubitemid 46631954)
32. Di Bonaventura G, Spedicato I, D'Antonio D, Robuffo I, Piccolomini R (2004) Biofilm formation by Stenotrophomonas maltophilia: modulation by quinolones, trimethoprim-sulfamethoxazole, and ceftazidime. Antimicrob Agents Chemother 48:151-160. (Pubitemid 38040191)
33. Pompilio A, Catavitello C, Picciani C, Confalone P, Piccolomini R, et al. (2010) Subinhibitory concentrations of moxifloxacin decrease adhesion and biofilm formation of Stenotrophomonas maltophilia from cystic fibrosis. J Med Microbiol 59:76-81.
34. Benelli R, Venè R, Bisacchi D, Garbisa S, Albini A (2002) Anti-invasive effects of green tea polyphenol epigallocatechin-3-gallate (EGCG), a natural inhibitor of metallo and serine proteases. Biol Chem 383:101-105. (Pubitemid 34224032)
35. Zaveri NT (2006) Green tea and its polyphenolic catechins: medicinal uses in cancer and noncancer applications. Life Sci 78:2073-2080.
36. Sudano Roccaro A, Blanco AR, Giuliano F, Rusciano D, Enea F (2004) Epigallocatechin-gallate enhances the activity of tetracycline in staphylococci by inhibiting its efflux from bacterial cells. Antimicrob Agents Chemother 48:1968-1973. (Pubitemid 38691584)
37. Evensen NA, Braun PC (2009) The effects of tea polyphenols on Candida albicans: inhibition of biofilm formation and proteasome inactivation. Can J Microbiol 55:1033-1039.
38. Isbrucker RA, Bausch J, Edwards JA, Wolz E (2006) Safety studies on epigallocatechin gallate (EGCG) preparations. Part 1: genotoxicity. Food Chem Toxicol 44:626-635.
39. Isbrucker RA, Edwards JA, Wolz E, Davidovich A, Bausch J (2006) Safety studies on epigallocatechin gallate (EGCG) preparations. Part 2: dermal, acute and short-term toxicity studies. Food Chem Toxicol 44:636-650.
40. Wu F, Sun H, Kluz T, Clancy HA, Kiok K, et al. (2012) Epigallocatechin-3-gallate (EGCG) protects against chromate-induced toxicity in vitro. Toxicol Appl Pharmacol 258:166-175.
41. O'Connell OJ, O'Farrell C, Harrison MJ, Eustace JA, Henry MT, et al. (2011) Nebulized hypertonic saline via positive expiratory pressure versus via jet nebulizer in patients with severe cystic fibrosis. Respir Care 56:771-775.
42. Yamada H, Tateishi M, Harada K, Ohashi T, Shimizu T, et al. (2006) A randomized clinical study of tea catechin inhalation effects on methicillin-resistant Staphylococcus aureus in disabled elderly patients. J Am Med Dir Assoc 7:79-83. (Pubitemid 43224465)
43. Navarro-Martínez MD, Navarro-Perán E, Cabezas-Herrera J, Ruiz-Gómez J, García-Cánovas F, et al. (2005) Antifolate activity of epigallocatechin gallate against Stenotrophomonas maltophilia. Antimicrob Agents Chemother 49:2914-2920. (Pubitemid 40917610)
44. Arakawa H, Maeda M, Okubo S, Shimamura T (2004) Role of hydrogen peroxide in bactericidal action of catechin. Biol Pharm Bull 27:277-281. (Pubitemid 41685465)
45. Bjarnsholt T, Alhede M, Alhede M, Eickhardt-Sørensen SR, Moser C, et al. (2013) The in vivo biofilm. Trends Microbiol. 21:466-474.